Please sign in to follow a disease.
Leishmaniasis
MONDO:0011989Infectious disease that is transmitted through the bite of hematophagous female phlebotomine sand flies. The clinical spectrum ranges from asymptomatic to clinically overt disease which can remain localized to the skin or disseminate to the upper oral and respiratory mucous membranes or throughout the reticulo-endothelial system. Three main clinical syndromes have been described: visceral (or Kala-Azar; with fever, weight loss, hepatosplenomegaly), cutaneous, and mucocutaneous leishmaniasis (cutaneous or mucocutaneous ulceration).
Also known as: cutaneous leishmaniasis (subtype), visceral leishmaniasis (subtype)
28 clinical trials for this condition and its sub-types, 8 tagged with Leishmaniasis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Leishmaniasis
-
Cutaneous leishmaniasis 14 trials
1 sub-type
- Leishmaniasis, diffuse cutaneous 0 trials
-
Visceral leishmaniasis 14 trials
-
Mucocutaneous leishmaniasis 3 trials
-
New oral drug candidate for two neglected parasitic diseases enters first human testing
Cure CompletedResearchers are running a first-in-human study of LXE408, an experimental oral tablet, to see how safe and well tolerated it is in healthy adults. About 88 healthy volunteers aged 18 to 65 will receive single or multiple ascending doses of LXE408 or a placebo. The study also meas…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Cure
Last updated Sep 11, 2026 00:00 UTC
-
Can a drug and heat combo beat a parasitic skin disease?
Disease control CompletedThis trial tests whether a drug called miltefosine, heat therapy (thermotherapy), or both together can safely and effectively treat skin lesions caused by the Leishmania tropica parasite in Pakistan. About 645 adults with up to four skin sores will be randomly assigned to one of …
Phase 3 • Sponsor: Medecins Sans Frontieres, Netherlands • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New hope against a deadly parasitic disease: LXE408 shows promise in phase II trial
Disease control CompletedThis study tested a new drug called LXE408 in 101 adults and teens with visceral leishmaniasis, a serious parasitic disease. Participants received one of two LXE408 doses or a standard treatment. The goal was to see if LXE408 could clear the parasite and improve symptoms by day 2…
Phase 2 • Sponsor: Drugs for Neglected Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Old drug, new hope? ivermectin tackles stubborn skin disease
Disease control CompletedThis early study tested whether the drug ivermectin could safely treat post-kala-azar dermal leishmaniasis (PKDL), a skin condition that can appear after recovery from visceral leishmaniasis. Ten otherwise healthy adults with PKDL took ivermectin pills for five days each month fo…
Early phase 1 • Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope against a deadly parasite: LXE408 trial shows promise
Disease control CompletedThis study tested a new drug called LXE408 in 52 adults with visceral leishmaniasis, a serious parasitic disease. The goal was to see if LXE408 could cure the infection by Day 28 compared to the standard treatment. The trial took place in Ethiopia and measured safety, drug levels…
Phase 2 • Sponsor: Drugs for Neglected Diseases • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Old drug, new hope? ivermectin tested for stubborn skin disease
Disease control CompletedThis early study tested whether the common anti-parasite drug ivermectin could treat post-kala-azar dermal leishmaniasis (PKDL), a skin condition that can spread a serious disease. Thirty people in Bangladesh received either ivermectin pills for 3 months or the standard drug milt…
Early phase 1 • Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh • Aim: Disease control
Last updated Jun 26, 2026 16:42 UTC
-
Blood tests could replace painful spleen sampling for deadly parasite
Diagnosis CompletedVisceral leishmaniasis is a fatal parasitic disease if left untreated, and current methods to check whether treatment worked require invasive sampling of the spleen or bone marrow. Researchers at Gondar University Hospital in Ethiopia are evaluating blood-based immune and molecul…
Sponsor: Foundation for Innovative New Diagnostics, Switzerland • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
New rapid test could speed up diagnosis of parasitic skin disease
Diagnosis CompletedThis study evaluated a new rapid test called CL Detect™ for diagnosing cutaneous leishmaniasis, a skin infection caused by parasites. Researchers tested 150 adults with skin ulcers to see how well the rapid test works compared to the standard method of looking at samples under a …
Sponsor: U.S. Army Medical Research and Development Command • Aim: Diagnosis
Last updated Jun 27, 2026 09:07 UTC
-
New biosensors aim to diagnose infections in minutes
Diagnosis CompletedThis study tested two new types of biosensor platforms to detect viruses, bacteria, and parasites in blood and respiratory samples. The goal was to see if these devices could be accurate, fast, and cheap alternatives to standard lab tests. Researchers enrolled 149 adults with or …
Sponsor: University of Bologna • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
Generic antifungal drug shows promise in early comparison study
Knowledge-focused CompletedThis study compared a new generic version of liposomal amphotericin B (an antifungal drug) to the brand-name version (AmBisome®) in 58 healthy Chinese adults. Each volunteer received a single dose of both drugs at different times to see if the generic works the same way in the bo…
Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Generic antifungal drug put to the test in healthy volunteers
Knowledge-focused CompletedThis study checked if a new version of the antifungal drug amphotericin B liposome works the same as the original. 42 healthy adults received a single dose of each version at different times. The goal was to see if the drug levels in the blood were similar enough to consider the …
Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC